We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
Prudential to use Vitech’s V3locity as core administration platform
The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC. In 2017, the FDA approved it as a CDx to identify patients who may be eligible for specific targeted therapies.